Formation Bio

Proud to announce that Formation Bio has acquired worldwide rights, excluding greater China, to FHND5032, a small-molecule miR-124 activator for autoimmune diseases. This marks our third acquisition in six months, and we plan to enter the clinic in 2026. Go behind the scenes of the acquisition with our team in our latest video.

Last week, we hosted the Princeton Entrepreneurship Club for a Q&A with our CEO @BenjamineYLiu to discuss our founding story, approaching problem-solving with an entrepreneurial mindset, and what it takes to build and scale a company in the AI age.

Next week, our team will be at @PHUSE_Global US Connect in Austin to share insights on bridging the gap between AI demos and production-ready tools in clinical development, and the open-source innovations shaping the future of clinical data. Learn more here: cdisc.org/events/educati…

Spotify: open.spotify.com/episode/5sy45o… Apple: podcasts.apple.com/us/podcast/epi… Explore open roles: formation.bio/careers

Our VP of Talent, Emily Gransky, recently joined The BioHub Podcast to discuss the talent acquisition strategy at Formation Bio — from values alignment in recruiting to AI’s current function in the talent space. Links to the full conversation and open roles on our team are below.

@a16z @BenjamineYLiu Full episode: youtube.com/watch?v=LYjxxm…

Great humans train great AI, and our models learn from the best in the business. On @a16z's Raising Health podcast, our CEO @BenjamineYLiu shares how Formation Bio is building this generation’s AI-native pharma company – starting with a team that has a proven track record. Link to full episode in the comments.

“Hopefully, the role of AI is that, at the end of the day, we all live longer and healthier lives.” ICYMI: Our panel on AI in medicine discovery and development provided an inside view of how AI is transforming the innovation process and therefore the lives of patients everywhere.

Indication landscaping is foundational to how we evaluate drug opportunities, but it’s complex, iterative, and data-heavy. In our latest post, we share how we built durable, AI-assisted workflows to support real-world indication research. formation.bio/blog/building-…

Raising the standard of care means delivering safer, more effective therapies for patients. Here’s how we built a flexible intelligence framework to structure clinical data, visualize efficacy–safety tradeoffs, and define success at scale. formation.bio/blog/where-dru…

“Assume your platform has no value. Its only value shows up through the assets you create.” Our CTO Dan Neil on why real value in biotech comes from outcomes, not platforms or hype. Read the full interview with @decodingbio: decodingbio.substack.com/p/scaling-bio-…

In the Loop, @billyperrigo's @TIME newsletter covering the people and ideas shaping AI right now, featured @BenjamineYLiu and Formation Bio this week. Read here: time.com/7372610/ai-dru…

AI-native ≠ more AI tools. Our CTO explains what it means in practice: changing the shape of a pharma company from labor-proportional to system-proportional scale, and building an institutional memory that appreciates rather than decays. formation.bio/blog/building-…

Full episode: youtube.com/watch?v=LYjxxm…

Why hasn’t a new big pharma been built since the 1980s? Watch our CEO @BenjamineYLiu break down the key reasons, and what it will finally take to do it again. Full episode link in the comments.

Our CEO @BenjamineYLiu is at @wef in Davos this week, and kicked things off yesterday speaking at the "Science as a Growth Engine" session hosted by WEF and GESDA. Proud to be part of the conversation on how AI can accelerate the path from discovery to treatment. #wef26

About 90% of drugs that enter clinical trials never make it to patients, but human genetics can significantly improve the odds. Here’s how Formation Bio built a human-in-the-loop pipeline to systematically apply genetic evidence across drug assets, helping us make better decisions earlier in development. formation.bio/blog/scaling-t…

Our Boston office opened yesterday! Excited to put down roots in one of the world's leading biotech hubs as we continue building our pipeline and bringing new medicines to patients.